<!DOCTYPE html>

<html lang="fa">
<meta content="text/html;charset=utf-8" http-equiv="content-type"/>
<head><title>Neurologic sarcoidosis</title><link href="/d/css/bootstrap.min.css" rel="stylesheet"/><link href="/d/css/icofont.min.css" rel="stylesheet"/><link href="/d/css/classy-nav.min.css" rel="stylesheet"/><link href="/d/css/animate.css" rel="stylesheet"/><link href="/d/css/owl.carousel.css" rel="stylesheet"/><link href="/d/css/magnific-popup.css" rel="stylesheet"/><link href="/d/css/owl.theme.default.min.css" rel="stylesheet"/><link href="/d/css/style.css" rel="stylesheet"/><link href="/d/css/rtl_edited.css" rel="stylesheet"/><link href="/d/css/responsive.css" rel="stylesheet"/><link href="https://medilib.ir/uptodate_assets/main.css" rel="stylesheet">
<style>

#myUL {
  list-style-type: none;
  padding: 0;
  margin: 0;
}

#myUL li a {
  border: 1px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #f6f6f6;
  padding: 12px;
  text-decoration: none;
  font-size: 16px;
  color: black;
  display: block
}

#myUL li a:hover:not(.header) {
  background-color: #eee;
}

#searchResult {

  list-style-type: none;
  padding: 0;
  padding-right: 20px;
}

#searchResult li a {
  border: .5px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #79bc21;
  padding: 7px;
  text-decoration: none;
  font-size: 14px;
  color: white;
  display: block
}

#searchResult li a:hover:not(.header) {
  background-color: #222;
}


#txtHint   {
  position: absolute;
  text-shadow: none;
  width: 100%;
  margin-top: -15px;
  padding-right: 10px;

  filter: alpha(opacity=95);
  -moz-opacity: 0.95;
  opacity: 1;
  z-index: 200;
}
.countBubl {
  background:#eb0029;
  color:#fff;
  padding:5px;
  margin-top: 50%;

}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(2) {
 width: 55%;
 padding-left: 20px;
}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(3) {
 width: 20%;
}
 #Uptodate_image {
      width: 50%;
  }#uptodate-area {
      /*z-index: 99;*/
  }
#uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > div:nth-child(2) {
 margin-left: 10px;
 margin-bottom: 6%;
}
@media (max-width: @screen-xs) {
    .countBubl {
        font-size: 4px ;
    }
    #uptodate_version {
        font-size: 4px ;
    }
}

@media (max-width: @screen-sm) {
    .countBubl {
        font-size: 14px ;
    }
}
@media  all and(max-width: 820) {
    #Uptodate_image {
        width: 80% ;
    }#uptodate-area {
        z-index: 99;
    }
}@media  all and (min-width: 820) and(max-width: 88820){
    #Uptodate_image {
        width: 100% !important;
    }
    .countBubl {
        font-size: 4px ;
    }
}
div.col-md-3:nth-child(3) {
 margin-top: 6%;
}

div.col-md-3:nth-child(3) > img:nth-child(1) {
 width: 100%;
 margin-left: 11px;
}

</style>
<style media="screen" type="text/css">
  .goback {
    width: 200px;
    height: 40px;
    line-height: 40px;
    position: fixed;
    display: none;
    font-size: 15px;
    background: #71c0fa;
    z-index: 1000;
    text-align: center;
    color: #ffffff;
    -webkit-border-radius: 1px;
    -moz-border-radius: 1px;
    border-radius: 50px;
    bottom: 3.8%;
    right: 2%;
}
  .buyPackage {
  width: 100px;
  height: 100px;
  line-height: 40px;
  position: fixed;
  display: none;
  font-size: 10px;
  background: #fa759e;
  z-index: 1000;
  text-align: center;
  color: #ffffff;
  -webkit-border-radius: 1px;
  -moz-border-radius: 1px;
  border-radius: 10px;
  top: 150px;
  right: 2%;
  text-align: center;
}
.uptodate-area {
  /*background-image: url(../../assets/img/news-letter-bg.jpg);*/
  background-position: center center;
  background-size: cover;
  background-repeat: no-repeat;
    background-attachment: fixed;
  position: relative;
}
.uptodate-area::before {
  content: '';
  position: absolute;
  left: 0;
  padding-top: 100px;
  width: 100%;
}
#references{
  display: none;
}
</style>
<style>
section.sticky {
  position: sticky;
  top: 0;
  background-color: #fff !important;
  /*z-index: 100;*/
  /*padding-top: 80px;*/

}
.m4inb{
    border: solid !important;
  }

  .newsletter-area::before {
       background: unset !important;
  }
p {
    color: #555;
}
</style>

<meta content="" name="description"/>
<link href="/d/img/favicon.png" rel="icon" type="image/png"/>
</link></head>
<body>
<!-- Start Main Menu Area -->

<br/>
<br/>
<br/>
<br/>
<div class="container">
<div class="row">
</div>
</div>




<section class="teacher-area ptb-10">
<div class="container">
</div>

<section class="course-details-area ptb-60">
<div class="container">
<div class="uptodate2" style="padding:50px 0px 50px 0px;direction: ltr;text-align: left;">
<h1 style="text-align:center">Neurologic sarcoidosis</h1>
<div class="utdArticleSection utdStyle" id="topicContent"><div id="topicTitle">Neurologic sarcoidosis</div> <div class="authorSectionElem"><div class="authorsElementsLeft"><dl id="topicContributors"><dt><span> </span>Author:</dt><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Barney J Stern, MD</a></dd><dt><span> </span>Section Editors:</dt><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Michael J Aminoff, MD, DSc</a></dd><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Talmadge E King, Jr, MD</a></dd><dt><span> </span>Deputy Editor:</dt><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Janet L Wilterdink, MD</a></dd></dl></div><div class="authorsElementsRight"><div id="literatureReviewDate"><div class="litReviewSingleLine"><bdi><span class="emphasis">Literature review current through:</span> Jan 2024.</bdi></div><div class="litReviewSingleLine"><bdi><span class="emphasis">This topic last updated:</span> Feb 11, 2020.</bdi></div></div></div></div><div id="topicWhatsNewContainer"></div><div id="topicText"><p class="headingAnchor" id="H1"><span class="h1">INTRODUCTION</span><span class="headingEndMark"> — </span>Neurologic complications occur in approximately 5 to 10 percent of patients with sarcoidosis [<a href="#rid1">1-4</a>]. Neurosarcoidosis is a diagnostic consideration in patients with known sarcoidosis who develop neurologic complaints and in patients presenting de novo with a constellation of findings consistent with the disease [<a href="#rid5">5,6</a>]. Approximately 50 percent of patients with neurosarcoidosis present with neurologic difficulties at the time sarcoidosis is first diagnosed. One-third of those with neurosarcoidosis have or develop more than one neurologic manifestation of their disease.</p><p>The diagnosis and management of neurosarcoidosis will be reviewed here. General issues related to sarcoidosis and its pathogenesis are discussed separately [<a href="#rid7">7</a>]. (See  <a class="medical medical_review" href="/d/html/4353.html" rel="external">"Clinical manifestations and diagnosis of sarcoidosis"</a> and  <a class="medical medical_review" href="/d/html/4365.html" rel="external">"Pathology and pathogenesis of sarcoidosis"</a>.)</p><p class="headingAnchor" id="H2"><span class="h1">CLINICAL FEATURES</span><span class="headingEndMark"> — </span>Any portion of the central or peripheral nervous system can be affected by sarcoidosis. Patients presenting with neurosarcoidosis may have no systemic features of the disease. In one case series, nonneurologic symptoms were present in less than one-fourth of patients and were most commonly anterior uveitis, cough and dyspnea, renal impairment, rash, and polyarthritis [<a href="#rid6">6</a>].</p><p class="headingAnchor" id="H3088563064"><span class="h2">Cranial mononeuropathy</span><span class="headingEndMark"> — </span>Peripheral facial nerve palsy develops in 25 to 50 percent of patients with neurosarcoidosis [<a href="#rid2">2,6,8</a>]. The facial nerve palsy can be unilateral or bilateral (simultaneous or sequential) and recurrent. Optic neuropathy [<a href="#rid9">9</a>] and cranial nerve VIII dysfunction can lead to intermittent or progressive visual, auditory, or vestibular dysfunction [<a href="#rid10">10</a>]. (See  <a class="medical medical_review" href="/d/html/5244.html" rel="external">"Optic neuropathies", section on 'Sarcoidosis'</a>.)</p><p class="headingAnchor" id="H1455670739"><span class="h2">Hypothalamic or pituitary involvement</span><span class="headingEndMark"> — </span>Neuroendocrine dysfunction typically occurs with hypothalamic inflammation, resulting in polyuria or disturbances in thirst, sleep, appetite, temperature, or libido. Hypothalamic or pituitary lesions may also cause thyroid, gonadal, or adrenal abnormalities [<a href="#rid6">6,11</a>]. (See  <a class="medical medical_review" href="/d/html/6636.html" rel="external">"Causes of hypopituitarism"</a>.)</p><p>One such manifestation, polyuria, can result from one or more factors in patients with sarcoidosis. Direct hypothalamic involvement can lead to central diabetes insipidus or primary polydipsia, while hypercalcemia (due to production of calcitriol by activated macrophages) can cause nephrogenic diabetes insipidus [<a href="#rid12">12</a>] (see  <a class="medical medical_review" href="/d/html/841.html" rel="external">"Hypercalcemia in granulomatous diseases"</a>). Thus, patients with sarcoidosis and polyuria may require a water restriction test to establish the correct diagnosis. (See  <a class="medical medical_review" href="/d/html/2381.html" rel="external">"Evaluation of patients with polyuria"</a>.)</p><p class="headingAnchor" id="H543411144"><span class="h2">Brain and spinal cord involvement</span></p><p class="bulletIndent1"><span class="glyph">●</span>Granulomatous inflammation in a perivascular distribution can involve the brain and produce focal or generalized seizures, or a restricted or generalized encephalopathy/vasculopathy [<a href="#rid6">6,8</a>]. Patients can present with cognitive or behavioral problems and/or focal neurologic deficits referable to the anatomic area involved. In rare cases, this manifests as a focal cerebral infarction [<a href="#rid13">13</a>].</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>A myelopathy or radiculopathy can occur if granulomatous inflammation affects the spinal cord [<a href="#rid6">6,8,14,15</a>]. The lesions are typically perivascular, can be extramedullary or intramedullary, and can involve the cauda equina.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Communicating or noncommunicating hydrocephalus may develop acutely or subacutely. Asymptomatic ventricular enlargement may be incidentally detected by imaging studies [<a href="#rid16">16</a>]. Sudden death can rarely result from acute obstruction to cerebrospinal fluid (CSF) flow, and neurologic deterioration can follow a lumbar puncture (LP).</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Meningeal involvement can take the form of either an acute aseptic meningitis or a chronic meningitis. Meningeal mass lesions also can develop.</p><p></p><p class="headingAnchor" id="H3068133245"><span class="h2">Peripheral neuropathy</span><span class="headingEndMark"> — </span>Peripheral neuropathic presentations include a mononeuropathy, mononeuritis multiplex, and generalized sensory, sensorimotor, and motor polyneuropathies [<a href="#rid17">17</a>]. The symptoms can be acute, subacute, or chronic; electromyography usually reveals an axonal neuropathy. In addition, an acute generalized demyelinating motor neuropathy similar to the Guillain-Barré syndrome also has been described [<a href="#rid18">18</a>] (see  <a class="medical medical_review" href="/d/html/5172.html" rel="external">"Guillain-Barré syndrome in adults: Treatment and prognosis"</a>) Perhaps the most unrecognized neuropathy presentation is that of a small fiber disorder manifesting as impaired perception of distal limb pain and temperature, often associated with paresthesias and hyperesthesia/dysesthesia, and autonomic dysfunction. When severe, symptoms and signs can extend to the torso [<a href="#rid19">19</a>].</p><p>Carpal tunnel syndrome appears to be more common among patients with sarcoidosis than the general population [<a href="#rid20">20-22</a>]. (See  <a class="medical medical_review" href="/d/html/5258.html" rel="external">"Carpal tunnel syndrome: Pathophysiology and risk factors"</a>.)</p><p class="headingAnchor" id="H3428287753"><span class="h2">Myopathy</span><span class="headingEndMark"> — </span>Muscle involvement includes asymptomatic microscopic nodules, isolated palpable nodules, an acute or chronic proximal myopathy, and muscle atrophy [<a href="#rid23">23</a>].</p><p class="headingAnchor" id="H3"><span class="h1">DIAGNOSTIC APPROACH</span><span class="headingEndMark"> — </span>Neurosarcoidosis is a diagnostic consideration in patients with known sarcoidosis who develop neurologic findings, although an intercurrent infection or malignancy must be excluded. Patients who develop a neurologic illness consistent with neurosarcoidosis but who are not known to have sarcoidosis present a diagnostic challenge.</p><p class="headingAnchor" id="H4"><span class="h2">Differential diagnosis</span><span class="headingEndMark"> — </span>The time course and details of presentation sometimes assist in differentiating neurosarcoidosis from other diseases, but many illnesses can present in a manner indistinguishable from neurosarcoidosis. Some representative situations include:</p><p class="bulletIndent1"><span class="glyph">●</span>Cranial nerve dysfunction – A patient with a peripheral facial nerve palsy may have an idiopathic Bell's palsy or a facial neuropathy associated with Lyme disease (see  <a class="medical medical_review" href="/d/html/7913.html" rel="external">"Clinical manifestations of Lyme disease in adults", section on 'Neurologic manifestations'</a>). An optic neuropathy may be indistinguishable from a multiple sclerosis-associated optic neuritis or neuromyelitis optica. Chronic infections, such as tuberculosis, and carcinomatous or lymphomatous meningitis should be considered in patients with multiple cranial nerve palsies.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Parenchymal lesions – Parenchymal granulomatous masses can masquerade as an astrocytoma or other primary or metastatic brain tumors. Multiple small white matter areas of increased T2 signal on magnetic resonance imaging (MRI) are a nonspecific finding and can be associated with multiple sclerosis or other inflammatory disorders. Spinal cord inflammation should prompt an evaluation for neuromyelitis optica.</p><p></p><p class="bulletIndent1">Ten cases of progressive multifocal leukoencephalopathy complicating sarcoidosis were described in one report; only eight had received immunosuppressive therapy, usually glucocorticoids alone [<a href="#rid24">24</a>]. Symptoms and MRI findings were mistakenly attributed to neurosarcoidosis in eight patients, perhaps contributing to the high case-fatality rate of 57 percent. (See  <a class="medical medical_review" href="/d/html/1694.html" rel="external">"Progressive multifocal leukoencephalopathy (PML): Epidemiology, clinical manifestations, and diagnosis"</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Encephalopathy – The encephalopathy/vasculopathy of sarcoidosis can be difficult to distinguish from syphilis or central nervous system (CNS) vasculitis (see  <a class="medical medical_review" href="/d/html/8230.html" rel="external">"Primary angiitis of the central nervous system in adults"</a>). Other rare, recently recognized, diagnostic considerations include autoimmune astrocytopathy [<a href="#rid25">25</a>] and common variable immunodeficiency [<a href="#rid26">26</a>].</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Meningeal disease – Sarcoidosis-associated aseptic meningitis is indistinguishable from that caused by viral infections, including HIV, or by tuberculosis or syphilis. A granulomatous meningeal mass may look like a meningioma on imaging studies. Immunoglobulin G4 (IgG4) pachymeningitis is a diagnostic consideration if there is prominent dural enhancement [<a href="#rid27">27</a>].</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Peripheral neuropathy – Other causes of neuropathy need to be considered depending upon the type of neuropathy present. Acquired etiologies of neuropathy include toxin exposure, metabolic abnormalities, and inflammatory disorders. Patients often have diabetic neuropathy from glucocorticoid-induced hyperglycemia.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Muscle weakness – Polymyositis and other causes of acquired muscle weakness need to be considered if a myopathic process is identified. (See  <a class="medical medical_review" href="/d/html/5155.html" rel="external">"Approach to the patient with muscle weakness"</a>.)</p><p></p><p>With the passage of time and with observation of the clinical course, some diagnostic considerations become more or less tenable. As an example, an immunosuppressed patient who remains relatively well over one to two years is unlikely to be suffering from an infection or malignancy. If deterioration occurs in conjunction with glucocorticoid therapy, complications of chronic glucocorticoid use, such as steroid-induced diabetes mellitus, myopathy, or epidural lipomatosis, may be contributing to the patient's decline. Opportunistic infections, such as cryptococcal meningitis or progressive multifocal leukoencephalopathy, can also occur in the immunosuppressed individual (see  <a class="medical medical_review" href="/d/html/2447.html" rel="external">"Clinical manifestations and diagnosis of Cryptococcus neoformans meningoencephalitis in patients without HIV"</a>). If deterioration in disease occurs after a period of clinical stability, an intercurrent problem should be considered initially, rather than an exacerbation of sarcoidosis.</p><p class="headingAnchor" id="H5"><span class="h2">Clinical evaluation</span><span class="headingEndMark"> — </span>If neurosarcoidosis is suspected, the patient should be evaluated for evidence of extraneural disease because obtaining nerve tissue for diagnostic evaluation is often difficult. Glucocorticoids can eliminate evidence of systemic inflammation, and the diagnostic evaluation should be pursued in a rapid fashion while withholding immunosuppressive therapy unless severe illness mandates its use.</p><p>The search for extraneural sarcoidosis should include a thorough evaluation of the skin, lymph nodes, and lungs (see  <a class="medical medical_review" href="/d/html/4353.html" rel="external">"Clinical manifestations and diagnosis of sarcoidosis"</a>). Other tests that may be useful are:</p><p class="bulletIndent1"><span class="glyph">●</span>Ophthalmologic examination.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Conjunctival biopsy has a low yield and is not recommended for the routine evaluation of patients for neurosarcoidosis [<a href="#rid28">28</a>].</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Endoscopic nasal and sinus examination.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>A chest x-ray or computed tomographic scan of the chest to look for hilar adenopathy or parenchymal changes consistent with pulmonary sarcoidosis. Positive findings suggestive of sarcoidosis on chest imaging have been reported in 24 to 68 percent of individuals who present with neurologic sarcoidosis [<a href="#rid6">6,8</a>].</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Serum angiotensin converting enzyme (ACE) assay, which may be helpful if elevated; however, an elevated serum ACE is not specific for sarcoidosis, and the ACE concentration may not necessarily be elevated if the patient has isolated neurosarcoidosis.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>In occasional cases, a magnetic resonance, gallium, or fluorodeoxyglucose positron emission tomographic scan may highlight otherwise occult areas of inflammation that might be amenable to biopsy.</p><p></p><p class="headingAnchor" id="H6"><span class="h2">Neurodiagnostic testing</span><span class="headingEndMark"> — </span>Neurologic evaluation, including consideration of a biopsy site, is especially important if no extraneural tissue is available for biopsy. Unfortunately, <strong>no</strong> neurodiagnostic tests are pathognomonic for neurosarcoidosis. However, neurodiagnostic tests help define the extent of disease and eliminate other diagnostic considerations, particularly infection and malignancy. Furthermore, a presumptive diagnosis of neurosarcoidosis is often made on the basis of MRI and lumbar puncture (LP) results in the appropriate clinical setting [<a href="#rid29">29</a>].</p><p class="headingAnchor" id="H7"><span class="h3">Neuroimaging</span><span class="headingEndMark"> — </span>The imaging procedure of choice for CNS disease is contrast-enhanced MRI [<a href="#rid8">8,11,30</a>]. Meningeal or parenchymal enhancement suggests active inflammation with disruption of the blood-brain barrier, and parenchymal or meningeal masses and hydrocephalus are easily identified. Involvement of the optic nerve or other cranial nerves can be documented, and spinal cord and cauda equina inflammation is well seen on targeted images. Multiple parenchymal nodules may actually represent inflammation extending along the Virchow-Robin spaces deep into the brain or spinal cord. In one series of 29 patients with neurosarcoidosis, approximately 40 percent demonstrated meningeal enhancement and/or multiple white matter lesions on MRI [<a href="#rid29">29</a>].</p><p>The MRI signs that are suggestive of spinal cord sarcoidosis include dorsal subpial gadolinium enhancement extending &gt;2 vertebral segments and persistent enhancement in spite of &gt;2 months of treatment [<a href="#rid31">31</a>].</p><p class="headingAnchor" id="H8"><span class="h3">Lumbar puncture</span><span class="headingEndMark"> — </span>Cerebrospinal fluid (CSF) abnormalities occur frequently in patients with CNS sarcoidosis [<a href="#rid6">6,8</a>]:</p><p class="bulletIndent1"><span class="glyph">●</span>The CSF opening pressure is elevated in approximately 10 percent of patients, and the total protein is increased in two-thirds of patients, typically up to 250 mg/dL. A pleocytosis is present in approximately 50 percent of patients.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Glucose can be normal or low, as can be seen in CNS infections or carcinomatous meningitis.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>A predominantly mononuclear cell pleocytosis is common.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>The IgG index can be elevated, and oligoclonal bands may be present.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>The CSF ACE concentration is occasionally elevated, but reliable normal values are lacking and CSF ACE may also be increased with infection or carcinomatous meningitis. The CSF ACE concentration can be elevated if the serum ACE level is increased and there is a leaky blood-brain barrier.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>CSF soluble interleukin 2 receptor (sIL-2r) levels can be elevated in CNS sarcoidosis; however, this test is not widely available and is not used routinely in the diagnosis of neurosarcoidosis. In one report, levels greater than 150 picograms/mL suggested neurosarcoidosis (61 percent sensitivity and 93 percent specificity) in comparison with healthy controls and other inflammatory diseases, such as multiple sclerosis and CNS vasculitis [<a href="#rid32">32</a>]. sIL-2r levels can be elevated in the setting of infection. </p><p></p><p>The presence of diffuse leptomeningeal enhancement is associated with an abnormal CSF profile. Patients with active disease tended to have higher CSF cell counts and total protein and hypoglycorrhachia [<a href="#rid33">33</a>].</p><p>Caution should be applied in performing an LP in patients with neurosarcoidosis if there is evidence of increased intracranial pressure. A funduscopic examination to exclude papilledema and an MRI to exclude ventricular enlargement, cerebral edema, and a mass lesion should precede LP [<a href="#rid34">34</a>].</p><p class="headingAnchor" id="H9"><span class="h3">Other tests</span><span class="headingEndMark"> — </span>Other diagnostic tests, such as electroencephalography, evoked potentials, and angiography, are occasionally indicated to further characterize disease involvement or exclude other conditions. Nerve conduction studies (NCS) and electromyography (EMG) can help localize and characterize neuromuscular lesions, depending on the clinical syndrome.</p><p>Although false-positive reactions to the Kveim-Siltzbach test are reported to be rare, the test has limited utility and is no longer used [<a href="#rid6">6</a>]. The test is not standardized, it is not universally available, and there are concerns regarding the transmission of HIV and hepatitis. (See  <a class="medical medical_review" href="/d/html/4365.html" rel="external">"Pathology and pathogenesis of sarcoidosis"</a>.)</p><p class="headingAnchor" id="H10"><span class="h2">Biopsy</span><span class="headingEndMark"> — </span>If the diagnosis remains in doubt, meningeal, brain, or spinal cord biopsy is occasionally indicated. Extraneural tissue biopsy from other clinically affected organs is generally preferable when possible, as it is less risky; skin, lymph node, and lung (transbronchial) biopsies can be of high yield [<a href="#rid6">6,8</a>]. Muscle and peripheral nerve biopsy, including an epidermal biopsy with quantitative nerve terminal analysis and sweat gland innervation to document small fiber sensory neuropathy [<a href="#rid35">35</a>], can all be easily performed for the appropriate syndrome.</p><p>Biopsy to establish the diagnosis, rather than empiric therapy, should be considered if there is no defined systemic disease. Biopsy, in an attempt to uncover an alternative neurologic diagnosis, should also be considered for patients with known systemic sarcoidosis and neurologic disease who are progressively deteriorating despite therapy [<a href="#rid36">36</a>].</p><p class="headingAnchor" id="H11"><span class="h1">TREATMENT</span><span class="headingEndMark"> — </span>There have been no randomized, double-blind, placebo-controlled treatment trials for neurosarcoidosis, but there is a consensus that these patients should be treated with glucocorticoids [<a href="#rid37">37</a>]. Treatment strategies with alternative agents have also been proposed (<a class="graphic graphic_algorithm graphicRef58324" href="/d/graphic/58324.html" rel="external">algorithm 1</a>). Sarcoidosis is typically a systemic disease, and treatment should address the burden of disease in all involved organs.</p><p class="headingAnchor" id="H12"><span class="h2">Glucocorticoids</span><span class="headingEndMark"> — </span>Glucocorticoids are the first-line agents for the treatment of neurosarcoidosis, and the dose and duration of therapy should be dictated by disease severity and response to therapy (see  <a class="medical medical_review" href="/d/html/4359.html" rel="external">"Treatment of pulmonary sarcoidosis: Initial approach"</a>). Different regimens are generally utilized depending upon the site of neurologic involvement:</p><p class="bulletIndent1"><span class="glyph">●</span>Patients with a peripheral facial nerve palsy or aseptic meningitis are often treated with <a class="drug drug_general" data-topicid="9809" href="/d/drug information/9809.html" rel="external">prednisone</a> 0.5 mg/kg per day for two weeks, and for a slightly longer duration by some physicians</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Patients with a myopathy or neuropathy are usually treated with <a class="drug drug_general" data-topicid="9809" href="/d/drug information/9809.html" rel="external">prednisone</a> 0.5 mg/kg per day for four weeks and their response assessed</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>A meningeal or parenchymal mass lesion, encephalopathy/vasculopathy, or symptomatic hydrocephalus often requires <a class="drug drug_general" data-topicid="9809" href="/d/drug information/9809.html" rel="external">prednisone</a> 1 to 1.5 mg/kg per day for four weeks before any benefit is appreciated</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Severely incapacitated or rapidly deteriorating patients may respond to intravenous <a class="drug drug_general" data-topicid="9639" href="/d/drug information/9639.html" rel="external">methylprednisolone</a> 20 mg/kg per day for three days followed by <a class="drug drug_general" data-topicid="9809" href="/d/drug information/9809.html" rel="external">prednisone</a> 1 to 1.5 mg/kg per day for two to four weeks</p><p></p><p>A slow <a class="drug drug_general" data-topicid="9809" href="/d/drug information/9809.html" rel="external">prednisone</a> taper should be considered in patients who are severely compromised or for whom a chronic course is likely. One useful approach is to allow the patient to stabilize or improve with four weeks of treatment and then to decrease the prednisone dose by 5 mg every two weeks as tolerated by symptoms. Exacerbations are most common when a prednisone dose of 10 mg/day is approached; thus, the dose should be decreased by 1 mg decrements every one to two weeks when the dose is near this level.</p><p>Acute deterioration is unusual if glucocorticoids are tapered in this fashion and patients are closely monitored. If the patient's symptoms recur, the <a class="drug drug_general" data-topicid="9809" href="/d/drug information/9809.html" rel="external">prednisone</a> dose should be doubled if the deterioration occurred at a dose of prednisone above 10 mg/day, or increased to 10 to 20 mg/day if a relapse occurred at lower doses.</p><p>Frequent clinical evaluation and periodic assessment of the extent of magnetic resonance imaging (MRI) enhancement (if enhancement was present on pretreatment scans) are generally helpful as glucocorticoids are weaned; monitoring of nerve conduction velocities and the electromyogram (EMG) is occasionally useful. By contrast, titrating therapy to normalize cerebrospinal fluid (CSF) parameters is <strong>not</strong> recommended, because excessive immunosuppression frequently results from this practice.</p><p class="headingAnchor" id="H13"><span class="h2">Other immunomodulatory therapies</span><span class="headingEndMark"> — </span>Patients who deteriorate in spite of aggressive glucocorticoid treatment, who cannot tolerate glucocorticoids, or who have a primary contraindication to glucocorticoid treatment may benefit from alternative therapies [<a href="#rid37">37-39</a>]. Expert opinion suggests that alternative therapies be considered early in the course of treatment for patients on high-dose glucocorticoid treatment and with manifestations likely to require prolonged treatment such as those with parenchymal inflammation, hydrocephalus, or optic neuropathy. There have been no prospective studies comparing various alternative treatments with one another in patients with neurosarcoidosis. A decision about the specific agent should be based upon ease of use, cost, and the desire to avoid the complications of a particular drug. There is little rigorous evidence that use of an alternative agent will result in a better functional clinical outcome than "optimal" glucocorticoid therapy, although 10 to 30 percent of patients improve to a greater extent than with glucocorticoid monotherapy [<a href="#rid38">38,39</a>]. Many patients treated with alternative agents respond most favorably if they are maintained on a modest glucocorticoid regimen (<a class="drug drug_general" data-topicid="9809" href="/d/drug information/9809.html" rel="external">prednisone</a> 10 to 20 mg/day). (See  <a class="medical medical_review" href="/d/html/4325.html" rel="external">"Treatment of pulmonary sarcoidosis refractory to initial therapy"</a>.)</p><p><a class="drug drug_general" data-topicid="9670" href="/d/drug information/9670.html" rel="external">Mycophenolate</a> mofetil, <a class="drug drug_general" data-topicid="9026" href="/d/drug information/9026.html" rel="external">azathioprine</a>, <a class="drug drug_general" data-topicid="9630" href="/d/drug information/9630.html" rel="external">methotrexate</a>, <a class="drug drug_general" data-topicid="9308" href="/d/drug information/9308.html" rel="external">cyclophosphamide</a>, and <a class="drug drug_general" data-topicid="10097" href="/d/drug information/10097.html" rel="external">leflunomide</a> are immunosuppressive agents that have been used to treat neurosarcoidosis [<a href="#rid6">6,39-44</a>]. In one small case series, mycophenolate mofetil was effective for treating disease affecting the central nervous system (CNS) but not sarcoid myopathy [<a href="#rid45">45</a>]. A retrospective multicenter study compared methotrexate and mycophenolate mofetil in preventing a relapse in patients with neurosarcoidosis [<a href="#rid46">46</a>]. Methotrexate treatment was associated with 0.2 relapses per year whereas mycophenolate mofetil was associated with 0.6 relapses per year. Adverse effects were more common with methotrexate than with mycophenolate mofetil. Dosing of azathioprine and cyclophosphamide should be targeted to achieve hematologic endpoints. We recommend lowering the total white blood cell count to approximately 3500 or the lymphocyte count to 1000 per mm<sup>3</sup>. <a class="drug drug_general" data-topicid="9616" href="/d/drug information/9616.html" rel="external">Rituximab</a> has been observed to be beneficial in refractory patients [<a href="#rid47">47</a>]; this author has observed benefit in several patients. Patient response to any specific drug cannot be predicted, and one should try two or three agents before concluding that the patient's disease is refractory.</p><p><a class="drug drug_general" data-topicid="8984" href="/d/drug information/8984.html" rel="external">Infliximab</a> is a chimeric human-murine antihuman antibody that specifically blocks the effect of tumor necrosis factor-alpha (TNF-alpha). Observational studies suggest that infliximab may be useful in selected patients with pulmonary and extrapulmonary sarcoidosis refractory to glucocorticoid therapy [<a href="#rid48">48-53</a>]. In one series of seven patients with glucocorticoid-refractory neurosarcoidosis, treatment with infliximab (with <a class="drug drug_general" data-topicid="9670" href="/d/drug information/9670.html" rel="external">mycophenolate</a> mofetil in six patients) was associated with symptom relief, regression of neurologic deficits, and a decrease in disease activity on MRI [<a href="#rid54">54</a>]. Another series reported stabilization and improvement in four patients with CNS manifestations of neurosarcoidosis [<a href="#rid55">55</a>]. A retrospective multicenter study of 66 patients with CNS sarcoidosis treated with infliximab for a median of 1.5 years found a beneficial MRI treatment response in 82.1 percent of patients with imaging follow-up. Clinical improvement was evident in 77.3 percent of patients. In 16 patients in remission when infliximab was discontinued, a recurrence developed in nine (56 percent) [<a href="#rid56">56</a>]. Use of infliximab requires an intravenous infusion (5 mg/kg of ideal body weight) initially, and periodically thereafter as the clinical course is monitored. <a class="drug drug_general" data-topicid="8583" href="/d/drug information/8583.html" rel="external">Adalimumab</a> is an injectable TNF-alpha antagonist that may be efficacious in the treatment of small fiber neuropathy [<a href="#rid57">57,58</a>]. Intravenous immunoglobulin is another option for the treatment of small fiber neuropathy [<a href="#rid59">59</a>]. (See  <a class="medical medical_review" href="/d/html/4325.html" rel="external">"Treatment of pulmonary sarcoidosis refractory to initial therapy"</a>.)</p><p class="headingAnchor" id="H14"><span class="h2">Surgical considerations</span><span class="headingEndMark"> — </span>Resection of a CNS mass lesion is rarely indicated, and patients may deteriorate following attempted resection of a mass. If biopsy of a mass lesion is consistent with sarcoidosis, resection usually should be deferred while appropriate medical management is pursued. If a mass lesion persists or enlarges despite "optimal" immunosuppressive therapy, resection may need to be considered.</p><p>A ventricular drain can be life-saving in patients with acute hydrocephalus [<a href="#rid6">6</a>]. Placement of a ventriculoperitoneal shunt is indicated for symptomatic hydrocephalus despite the fact that the presence of a foreign object in an immunocompromised patient predisposes to infection. Immunosuppressive therapy should continue immediately following shunt placement to treat the underlying inflammatory process. Inflammation due to neurosarcoidosis often leads to shunt obstruction, necessitating multiple shunt revisions.</p><p class="headingAnchor" id="H15"><span class="h2">Radiation therapy</span><span class="headingEndMark"> — </span>Cranial or spinal irradiation has been used for refractory disease and should be considered if patients fail glucocorticoid therapy and trials of at least two alternative agents [<a href="#rid60">60</a>]. The modality has also occasionally been required for patients with acute, life-threatening disease. Immunosuppression is generally continued during radiation therapy, albeit at less intense levels.</p><p class="headingAnchor" id="H16"><span class="h2">General measures</span><span class="headingEndMark"> — </span>Endocrinologic deficiencies should be corrected [<a href="#rid11">11</a>]. Hypothalamic hypothyroidism should be excluded if a patient has CNS disease beyond a single cranial nerve deficit. This requires measurement of the T4 concentration, since serum thyrotropin (TSH) concentrations may be normal or low (see  <a class="medical medical_review" href="/d/html/7893.html" rel="external">"Diagnosis of and screening for hypothyroidism in nonpregnant adults"</a>). Testosterone deficiency is often clinically silent and should be sought in patients with symptoms or other signs of hypothalamic or pituitary disease. Treatment of an otherwise occult testosterone deficiency may help preserve muscle and bone mass.</p><p>Patients who require prolonged glucocorticoid therapy may benefit from early dietary counseling and an exercise program to mitigate weight gain and debilitation. Intervention to prevent excessive bone loss is appropriate. (See  <a class="medical medical_review" href="/d/html/2034.html" rel="external">"Prevention and treatment of glucocorticoid-induced osteoporosis"</a>.)</p><p class="headingAnchor" id="H17"><span class="h1">PROGNOSIS</span><span class="headingEndMark"> — </span>Patients with neurosarcoidosis can have a monophasic illness (approximately two-thirds of patients), a relapsing-remitting course, or progressive disease punctuated by episodic deteriorations [<a href="#rid6">6,61,62</a>]. Historically, approximately 10 percent of patients die as a direct result of the inflammatory process or its treatment; current management strategies have substantially improved patient survival. These high-risk patients typically have central nervous system (CNS) parenchymal disease or hydrocephalus and are often profoundly immunocompromised due to treatment. Patients with sarcoidosis are at risk for cancer, particularly lymphoma, by virtue of the disease or treatment with immunosuppressive drugs other than glucocorticoids.</p><p>The long-term course of neurosarcoidosis has not been clearly defined. Nevertheless, some generalizations are possible based upon observations of treated individuals:</p><p class="bulletIndent1"><span class="glyph">●</span>Patients with a peripheral facial nerve palsy tend to improve over two to four weeks. Most other cranial mononeuropathies follow a similar course [<a href="#rid8">8</a>].</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Optic neuropathy can improve over several weeks, but some patients have a progressive course ending in blindness [<a href="#rid8">8</a>]. </p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Aseptic meningitis usually resolves over several weeks, although an asymptomatic chronic pleocytosis can persist.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Meningeal or parenchymal mass lesions often exhibit a prolonged course, although some mass lesions resolve over time.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Endocrinopathies rarely improve with immunosuppression; as a result, chronic hormonal replacement therapy is usually necessary.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Hypothalamic vegetative symptoms can respond to treatment but rarely resolve spontaneously.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>The encephalopathy/vasculopathy of sarcoidosis is typically progressive albeit with periods of improvement and deterioration.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Seizure control is usually not difficult as long as the underlying inflammatory process is controlled [<a href="#rid63">63</a>].</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Ventricular enlargement can be asymptomatic or can cause acute or chronic deterioration.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Peripheral neuropathic and myopathic illness tends to be chronic and progressive, although remissions are possible.</p><p></p><p class="headingAnchor" id="H4221603564"><span class="h1">SOCIETY GUIDELINE LINKS</span><span class="headingEndMark"> — </span>Links to society and government-sponsored guidelines from selected countries and regions around the world are provided separately. (See  <a class="medical medical_society_guidelines" href="/d/html/116637.html" rel="external">"Society guideline links: Sarcoidosis"</a>.)</p><p class="headingAnchor" id="H7966393"><span class="h1">SUMMARY AND RECOMMENDATIONS</span></p><p class="bulletIndent1"><span class="glyph">●</span>Neurologic complications potentially affecting any portion of the central or peripheral nervous system occur in approximately 5 to 10 percent of patients with sarcoidosis and can be the presenting feature. Common syndromes include a cranial mononeuropathy, neuroendocrine dysfunction, a focal or multifocal encephalopathy, myelopathy, hydrocephalus, aseptic meningitis, peripheral neuropathy, or myopathy. (See <a class="local">'Clinical features'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Diagnostic evaluation requires distinguishing neurosarcoidosis from a variety of other inflammatory, neoplastic, and infectious conditions. (See <a class="local">'Differential diagnosis'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>A thorough evaluation for systemic sarcoidosis (eg, chest imaging, positron emission tomography scan) can expedite the evaluation by providing tissue that is accessible for biopsy. In the absence of systemic sarcoidosis, testing that may be helpful includes magnetic resonance imaging (MRI) of the affected area, cerebrospinal fluid (CSF) evaluation (with expected findings described above), and serum angiotensin converting enzyme (ACE) level. None of these tests have perfect sensitivity and specificity. (See <a class="local">'Clinical evaluation'</a> above and <a class="local">'Neurodiagnostic testing'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Biopsy should be considered in all patients in whom diagnosis remains in doubt, as treatment is prolonged and associated with complications. (See <a class="local">'Biopsy'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>We suggest glucocorticoid therapy as the first treatment in a patient with neurosarcoidosis (<a class="grade" href="https://medilib.ir/uptodate/show/grade_5" rel="external">Grade 2B</a>). The dose and duration are determined by the severity of the illness and treatment response, with some suggested guidelines outlined above. (See <a class="local">'Glucocorticoids'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Patients who deteriorate in spite of aggressive glucocorticoid treatment, who cannot tolerate glucocorticoids, who have a primary contraindication to glucocorticoid treatment, or who are predicted to have chronic, aggressive disease may benefit from alternative therapies. Benefits have been observed with <a class="drug drug_general" data-topicid="9670" href="/d/drug information/9670.html" rel="external">mycophenolate</a> mofetil, <a class="drug drug_general" data-topicid="9026" href="/d/drug information/9026.html" rel="external">azathioprine</a>, <a class="drug drug_general" data-topicid="9630" href="/d/drug information/9630.html" rel="external">methotrexate</a>, <a class="drug drug_general" data-topicid="9308" href="/d/drug information/9308.html" rel="external">cyclophosphamide</a>, <a class="drug drug_general" data-topicid="8984" href="/d/drug information/8984.html" rel="external">infliximab</a>, or <a class="drug drug_general" data-topicid="8583" href="/d/drug information/8583.html" rel="external">adalimumab</a>, to mention a few select drugs. (See <a class="local">'Other immunomodulatory therapies'</a> above.)</p><p></p><p class="bulletIndent1">Radiation can be attempted in patients with central nervous system (CNS) disease refractory to medical treatment. (See <a class="local">'Radiation therapy'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Patients with neurosarcoidosis can have a monophasic illness (approximately two-thirds of patients), a relapsing-remitting course, or progressive disease punctuated by episodic deteriorations. (See <a class="local">'Prognosis'</a> above.)</p></div><div class="headingAnchor" id="references"><ol id="reference"><li><a class="nounderline abstract_t">Burns TM. Neurosarcoidosis. Arch Neurol 2003; 60:1166.</a></li><li><a class="nounderline abstract_t">Stern BJ, Krumholz A, Johns C, et al. Sarcoidosis and its neurological manifestations. Arch Neurol 1985; 42:909.</a></li><li><a class="nounderline abstract_t">Joseph FG, Scolding NJ. Sarcoidosis of the nervous system. Pract Neurol 2007; 7:234.</a></li><li><a class="nounderline abstract_t">Terushkin V, Stern BJ, Judson MA, et al. Neurosarcoidosis: presentations and management. Neurologist 2010; 16:2.</a></li><li><a class="nounderline abstract_t">Scott TF. Neurosarcoidosis: progress and clinical aspects. Neurology 1993; 43:8.</a></li><li><a class="nounderline abstract_t">Joseph FG, Scolding NJ. Neurosarcoidosis: a study of 30 new cases. J Neurol Neurosurg Psychiatry 2009; 80:297.</a></li><li><a class="nounderline abstract_t">Lareau CA, Adrianto I, Levin AM, et al. Fine mapping of chromosome 15q25 implicates ZNF592 in neurosarcoidosis patients. Ann Clin Transl Neurol 2015; 2:972.</a></li><li><a class="nounderline abstract_t">Pawate S, Moses H, Sriram S. Presentations and outcomes of neurosarcoidosis: a study of 54 cases. QJM 2009; 102:449.</a></li><li><a class="nounderline abstract_t">Kidd DP, Burton BJ, Graham EM, Plant GT. Optic neuropathy associated with systemic sarcoidosis. Neurol Neuroimmunol Neuroinflamm 2016; 3:e270.</a></li><li><a class="nounderline abstract_t">Imran TF, Nizami S, Eyzner I, et al. Vertigo as a predominant manifestation of neurosarcoidosis. Case Rep Med 2015; 2015:397046.</a></li><li><a class="nounderline abstract_t">Bihan H, Christozova V, Dumas JL, et al. Sarcoidosis: clinical, hormonal, and magnetic resonance imaging (MRI) manifestations of hypothalamic-pituitary disease in 9 patients and review of the literature. Medicine (Baltimore) 2007; 86:259.</a></li><li><a class="nounderline abstract_t">Stuart CA, Neelon FA, Lebovitz HE. Disordered control of thirst in hypothalamic-pituitary sarcoidosis. N Engl J Med 1980; 303:1078.</a></li><li><a class="nounderline abstract_t">Navi BB, DeAngelis LM. Sarcoidosis presenting as brainstem ischemic stroke. Neurology 2009; 72:1021.</a></li><li><a class="nounderline abstract_t">Junger SS, Stern BJ, Levine SR, et al. Intramedullary spinal sarcoidosis: clinical and magnetic resonance imaging characteristics. Neurology 1993; 43:333.</a></li><li><a class="nounderline abstract_t">Reda HM, Taylor SW, Klein CJ, Boes CJ. A case of sensory ataxia as the presenting manifestation of neurosarcoidosis. Muscle Nerve 2011; 43:900.</a></li><li><a class="nounderline abstract_t">Brouwer MC, de Gans J, Willemse RB, van de Beek D. Neurological picture. Sarcoidosis presenting with hydrocephalus. J Neurol Neurosurg Psychiatry 2009; 80:550.</a></li><li><a class="nounderline abstract_t">Zuniga G, Ropper AH, Frank J. Sarcoid peripheral neuropathy. Neurology 1991; 41:1558.</a></li><li><a class="nounderline abstract_t">Saifee TA, Reilly MM, Ako E, et al. Sarcoidosis presenting as acute inflammatory demyelinating polyradiculoneuropathy. Muscle Nerve 2011; 43:296.</a></li><li><a class="nounderline abstract_t">Tavee J, Culver D. Sarcoidosis and small-fiber neuropathy. Curr Pain Headache Rep 2011; 15:201.</a></li><li><a class="nounderline abstract_t">Niemer GW, Bolster MB, Buxbaum L, Judson MA. Carpal tunnel syndrome in sarcoidosis. Sarcoidosis Vasc Diffuse Lung Dis 2001; 18:296.</a></li><li><a class="nounderline abstract_t">Nakatani-Enomoto S, Aizawa H, Koyama S, et al. Transient swelling of peripheral nerves in a case of neurosarcoidosis. Intern Med 2004; 43:1078.</a></li><li><a class="nounderline abstract_t">SHAMBAUGH GE, CIRKSENA WJ, NEWCOMER KL. CARPAL TUNNEL SYNDROME AS MANIFESTATION OF SARCOIDOSIS. Arch Intern Med 1964; 114:830.</a></li><li><a class="nounderline abstract_t">Ando DG, Lynch JP 3rd, Fantone JC 3rd. Sarcoid myopathy with elevated creatine phosphokinase. Am Rev Respir Dis 1985; 131:298.</a></li><li><a class="nounderline abstract_t">Jamilloux Y, Néel A, Lecouffe-Desprets M, et al. Progressive multifocal leukoencephalopathy in patients with sarcoidosis. Neurology 2014; 82:1307.</a></li><li><a class="nounderline abstract_t">Flanagan EP, Hinson SR, Lennon VA, et al. Glial fibrillary acidic protein immunoglobulin G as biomarker of autoimmune astrocytopathy: Analysis of 102 patients. Ann Neurol 2017; 81:298.</a></li><li><a class="nounderline abstract_t">Nguyen JT, Green A, Wilson MR, et al. Neurologic Complications of Common Variable Immunodeficiency. J Clin Immunol 2016; 36:793.</a></li><li><a class="nounderline abstract_t">Stone JH, Brito-Zerón P, Bosch X, Ramos-Casals M. Diagnostic Approach to the Complexity of IgG4-Related Disease. Mayo Clin Proc 2015; 90:927.</a></li><li><a class="nounderline abstract_t">Pichler MR, Flanagan EP, Aksamit AJ, et al. Conjunctival biopsy to diagnose neurosarcoidosis in patients with inflammatory nervous system disease of unknown etiology. Neurol Clin Pract 2015; 5:216.</a></li><li><a class="nounderline abstract_t">Zajicek JP, Scolding NJ, Foster O, et al. Central nervous system sarcoidosis--diagnosis and management. QJM 1999; 92:103.</a></li><li><a class="nounderline abstract_t">Sherman JL, Stern BJ. Sarcoidosis of the CNS: comparison of unenhanced and enhanced MR images. AJNR Am J Neuroradiol 1990; 11:915.</a></li><li><a class="nounderline abstract_t">Flanagan EP, Kaufmann TJ, Krecke KN, et al. Discriminating long myelitis of neuromyelitis optica from sarcoidosis. Ann Neurol 2016; 79:437.</a></li><li><a class="nounderline abstract_t">Petereit HF, Reske D, Tumani H, et al. Soluble CSF interleukin 2 receptor as indicator of neurosarcoidosis. J Neurol 2010; 257:1855.</a></li><li><a class="nounderline abstract_t">Wengert O, Rothenfusser-Korber E, Vollrath B, et al. Neurosarcoidosis: correlation of cerebrospinal fluid findings with diffuse leptomeningeal gadolinium enhancement on MRI and clinical disease activity. J Neurol Sci 2013; 335:124.</a></li><li><a class="nounderline abstract_t">Scott TF. Cerebral herniation after lumbar puncture in sarcoid meningitis. Clin Neurol Neurosurg 2000; 102:26.</a></li><li><a class="nounderline abstract_t">Bakkers M, Merkies IS, Lauria G, et al. Intraepidermal nerve fiber density and its application in sarcoidosis. Neurology 2009; 73:1142.</a></li><li><a class="nounderline abstract_t">Peeples DM, Stern BJ, Jiji V, Sahni KS. Germ cell tumors masquerading as central nervous system sarcoidosis. Arch Neurol 1991; 48:554.</a></li><li><a class="nounderline abstract_t">Stern BJ, Corbett J. Neuro-ophthalmologic Manifestations of Sarcoidosis. Curr Treat Options Neurol 2007; 9:63.</a></li><li><a class="nounderline abstract_t">Agbogu BN, Stern BJ, Sewell C, Yang G. Therapeutic considerations in patients with refractory neurosarcoidosis. Arch Neurol 1995; 52:875.</a></li><li><a class="nounderline abstract_t">Scott TF, Yandora K, Valeri A, et al. Aggressive therapy for neurosarcoidosis: long-term follow-up of 48 treated patients. Arch Neurol 2007; 64:691.</a></li><li><a class="nounderline abstract_t">Stern BJ, Schonfeld SA, Sewell C, et al. The treatment of neurosarcoidosis with cyclosporine. Arch Neurol 1992; 49:1065.</a></li><li><a class="nounderline abstract_t">Sharma OP. Neurosarcoidosis: a personal perspective based on the study of 37 patients. Chest 1997; 112:220.</a></li><li><a class="nounderline abstract_t">Lower EE, Broderick JP, Brott TG, Baughman RP. Diagnosis and management of neurological sarcoidosis. Arch Intern Med 1997; 157:1864.</a></li><li><a class="nounderline abstract_t">Doty JD, Mazur JE, Judson MA. Treatment of corticosteroid-resistant neurosarcoidosis with a short-course cyclophosphamide regimen. Chest 2003; 124:2023.</a></li><li><a class="nounderline abstract_t">Tikoo RK, Kupersmith MJ, Finlay JL. Treatment of refractory neurosarcoidosis with cladribine. N Engl J Med 2004; 350:1798.</a></li><li><a class="nounderline abstract_t">Androdias G, Maillet D, Marignier R, et al. Mycophenolate mofetil may be effective in CNS sarcoidosis but not in sarcoid myopathy. Neurology 2011; 76:1168.</a></li><li><a class="nounderline abstract_t">Bitoun S, Bouvry D, Borie R, et al. Treatment of neurosarcoidosis: A comparative study of methotrexate and mycophenolate mofetil. Neurology 2016; 87:2517.</a></li><li><a class="nounderline abstract_t">Bomprezzi R, Pati S, Chansakul C, Vollmer T. A case of neurosarcoidosis successfully treated with rituximab. Neurology 2010; 75:568.</a></li><li><a class="nounderline abstract_t">Pritchard C, Nadarajah K. Tumour necrosis factor alpha inhibitor treatment for sarcoidosis refractory to conventional treatments: a report of five patients. Ann Rheum Dis 2004; 63:318.</a></li><li><a class="nounderline abstract_t">Morcos Z. Refractory neurosarcoidosis responding to infliximab. Neurology 2003; 60:1220.</a></li><li><a class="nounderline abstract_t">Katz JM, Bruno MK, Winterkorn JM, Nealon N. The pathogenesis and treatment of optic disc swelling in neurosarcoidosis: a unique therapeutic response to infliximab. Arch Neurol 2003; 60:426.</a></li><li><a class="nounderline abstract_t">Pettersen JA, Zochodne DW, Bell RB, et al. Refractory neurosarcoidosis responding to infliximab. Neurology 2002; 59:1660.</a></li><li><a class="nounderline abstract_t">Carter JD, Valeriano J, Vasey FB, Bognar B. Refractory neurosarcoidosis: a dramatic response to infliximab. Am J Med 2004; 117:277.</a></li><li><a class="nounderline abstract_t">Hoitsma E, Faber CG, van Santen-Hoeufft M, et al. Improvement of small fiber neuropathy in a sarcoidosis patient after treatment with infliximab. Sarcoidosis Vasc Diffuse Lung Dis 2006; 23:73.</a></li><li><a class="nounderline abstract_t">Moravan M, Segal BM. Treatment of CNS sarcoidosis with infliximab and mycophenolate mofetil. Neurology 2009; 72:337.</a></li><li><a class="nounderline abstract_t">Santos E, Shaunak S, Renowden S, Scolding NJ. Treatment of refractory neurosarcoidosis with Infliximab. J Neurol Neurosurg Psychiatry 2010; 81:241.</a></li><li><a class="nounderline abstract_t">Gelfand JM, Bradshaw MJ, Stern BJ, et al. Infliximab for the treatment of CNS sarcoidosis: A multi-institutional series. Neurology 2017; 89:2092.</a></li><li><a class="nounderline abstract_t">Marques IB, Giovannoni G, Marta M. Mononeuritis multiplex as the first presentation of refractory sarcoidosis responsive to etanercept. BMC Neurol 2014; 14:237.</a></li><li><a class="nounderline abstract_t">Wijnen PA, Cremers JP, Nelemans PJ, et al. Association of the TNF-α G-308A polymorphism with TNF-inhibitor response in sarcoidosis. Eur Respir J 2014; 43:1730.</a></li><li><a class="nounderline abstract_t">Parambil JG, Tavee JO, Zhou L, et al. Efficacy of intravenous immunoglobulin for small fiber neuropathy associated with sarcoidosis. Respir Med 2011; 105:101.</a></li><li><a class="nounderline abstract_t">Menninger MD, Amdur RJ, Marcus RB Jr. Role of radiotherapy in the treatment of neurosarcoidosis. Am J Clin Oncol 2003; 26:e115.</a></li><li><a class="nounderline abstract_t">Luke RA, Stern BJ, Krumholz A, Johns CJ. Neurosarcoidosis: the long-term clinical course. Neurology 1987; 37:461.</a></li><li><a class="nounderline abstract_t">Allen RK, Sellars RE, Sandstrom PA. A prospective study of 32 patients with neurosarcoidosis. Sarcoidosis Vasc Diffuse Lung Dis 2003; 20:118.</a></li><li><a class="nounderline abstract_t">Krumholz A, Stern BJ, Stern EG. Clinical implications of seizures in neurosarcoidosis. Arch Neurol 1991; 48:842.</a></li></ol></div><div id="topicVersionRevision">Topic 4834 Version 12.0</div></div>
<div class="row">
<div class="col-12">
<h4 style="text-align: center;padding: 20px;color: cadetblue;">References</h4>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/12925378" id="rid0" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>1 : Neurosarcoidosis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/3896208" id="rid1" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>2 : Sarcoidosis and its neurological manifestations.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17636138" id="rid2" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>3 : Sarcoidosis of the nervous system.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/20065791" id="rid3" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>4 : Neurosarcoidosis: presentations and management.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/8380910" id="rid4" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>5 : Neurosarcoidosis: progress and clinical aspects.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/18977817" id="rid5" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>6 : Neurosarcoidosis: a study of 30 new cases.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/26478897" id="rid6" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>7 : Fine mapping of chromosome 15q25 implicates ZNF592 in neurosarcoidosis patients.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19383611" id="rid7" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>8 : Presentations and outcomes of neurosarcoidosis: a study of 54 cases.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/27536707" id="rid8" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>9 : Optic neuropathy associated with systemic sarcoidosis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/25922606" id="rid9" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>10 : Vertigo as a predominant manifestation of neurosarcoidosis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17873755" id="rid10" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>11 : Sarcoidosis: clinical, hormonal, and magnetic resonance imaging (MRI) manifestations of hypothalamic-pituitary disease in 9 patients and review of the literature.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/7421913" id="rid11" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>12 : Disordered control of thirst in hypothalamic-pituitary sarcoidosis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19289743" id="rid12" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>13 : Sarcoidosis presenting as brainstem ischemic stroke.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/8437698" id="rid13" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>14 : Intramedullary spinal sarcoidosis: clinical and magnetic resonance imaging characteristics.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/21607973" id="rid14" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>15 : A case of sensory ataxia as the presenting manifestation of neurosarcoidosis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19372289" id="rid15" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>16 : Neurological picture. Sarcoidosis presenting with hydrocephalus.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/1656324" id="rid16" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>17 : Sarcoid peripheral neuropathy.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/21254101" id="rid17" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>18 : Sarcoidosis presenting as acute inflammatory demyelinating polyradiculoneuropathy.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/21298560" id="rid18" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>19 : Sarcoidosis and small-fiber neuropathy.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/11587102" id="rid19" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>20 : Carpal tunnel syndrome in sarcoidosis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15609707" id="rid20" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>21 : Transient swelling of peripheral nerves in a case of neurosarcoidosis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/14211600" id="rid21" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>22 : CARPAL TUNNEL SYNDROME AS MANIFESTATION OF SARCOIDOSIS.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/3970459" id="rid22" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>23 : Sarcoid myopathy with elevated creatine phosphokinase.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/24610328" id="rid23" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>24 : Progressive multifocal leukoencephalopathy in patients with sarcoidosis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/28120349" id="rid24" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>25 : Glial fibrillary acidic protein immunoglobulin G as biomarker of autoimmune astrocytopathy: Analysis of 102 patients.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/27704236" id="rid25" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>26 : Neurologic Complications of Common Variable Immunodeficiency.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/26141331" id="rid26" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>27 : Diagnostic Approach to the Complexity of IgG4-Related Disease.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/29443212" id="rid27" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>28 : Conjunctival biopsy to diagnose neurosarcoidosis in patients with inflammatory nervous system disease of unknown etiology.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/10209662" id="rid28" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>29 : Central nervous system sarcoidosis--diagnosis and management.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/2120996" id="rid29" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>30 : Sarcoidosis of the CNS: comparison of unenhanced and enhanced MR images.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/26677112" id="rid30" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>31 : Discriminating long myelitis of neuromyelitis optica from sarcoidosis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/20556411" id="rid31" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>32 : Soluble CSF interleukin 2 receptor as indicator of neurosarcoidosis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/24071064" id="rid32" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>33 : Neurosarcoidosis: correlation of cerebrospinal fluid findings with diffuse leptomeningeal gadolinium enhancement on MRI and clinical disease activity.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/10717399" id="rid33" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>34 : Cerebral herniation after lumbar puncture in sarcoid meningitis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19805731" id="rid34" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>35 : Intraepidermal nerve fiber density and its application in sarcoidosis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/1850595" id="rid35" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>36 : Germ cell tumors masquerading as central nervous system sarcoidosis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17288891" id="rid36" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>37 : Neuro-ophthalmologic Manifestations of Sarcoidosis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/7661724" id="rid37" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>38 : Therapeutic considerations in patients with refractory neurosarcoidosis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17502468" id="rid38" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>39 : Aggressive therapy for neurosarcoidosis: long-term follow-up of 48 treated patients.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/1329698" id="rid39" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>40 : The treatment of neurosarcoidosis with cyclosporine.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/9228380" id="rid40" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>41 : Neurosarcoidosis: a personal perspective based on the study of 37 patients.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/9290546" id="rid41" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>42 : Diagnosis and management of neurological sarcoidosis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/14605084" id="rid42" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>43 : Treatment of corticosteroid-resistant neurosarcoidosis with a short-course cyclophosphamide regimen.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15103013" id="rid43" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>44 : Treatment of refractory neurosarcoidosis with cladribine.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/21444902" id="rid44" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>45 : Mycophenolate mofetil may be effective in CNS sarcoidosis but not in sarcoid myopathy.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/27856779" id="rid45" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>46 : Treatment of neurosarcoidosis: A comparative study of methotrexate and mycophenolate mofetil.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/20697110" id="rid46" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>47 : A case of neurosarcoidosis successfully treated with rituximab.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/14962969" id="rid47" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>48 : Tumour necrosis factor alpha inhibitor treatment for sarcoidosis refractory to conventional treatments: a report of five patients.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/12682347" id="rid48" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>49 : Refractory neurosarcoidosis responding to infliximab.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/12633155" id="rid49" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>50 : The pathogenesis and treatment of optic disc swelling in neurosarcoidosis: a unique therapeutic response to infliximab.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/12451224" id="rid50" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>51 : Refractory neurosarcoidosis responding to infliximab.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15308439" id="rid51" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>52 : Refractory neurosarcoidosis: a dramatic response to infliximab.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16933474" id="rid52" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>53 : Improvement of small fiber neuropathy in a sarcoidosis patient after treatment with infliximab.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19171830" id="rid53" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>54 : Treatment of CNS sarcoidosis with infliximab and mycophenolate mofetil.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/18977810" id="rid54" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>55 : Treatment of refractory neurosarcoidosis with Infliximab.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/29030454" id="rid55" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>56 : Infliximab for the treatment of CNS sarcoidosis: A multi-institutional series.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/25494723" id="rid56" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>57 : Mononeuritis multiplex as the first presentation of refractory sarcoidosis responsive to etanercept.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/24558177" id="rid57" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>58 : Association of the TNF-αG-308A polymorphism with TNF-inhibitor response in sarcoidosis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/20926271" id="rid58" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>59 : Efficacy of intravenous immunoglobulin for small fiber neuropathy associated with sarcoidosis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/12902908" id="rid59" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>60 : Role of radiotherapy in the treatment of neurosarcoidosis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/3822138" id="rid60" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>61 : Neurosarcoidosis: the long-term clinical course.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/12870721" id="rid61" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>62 : A prospective study of 32 patients with neurosarcoidosis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/1898259" id="rid62" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>63 : Clinical implications of seizures in neurosarcoidosis.</p>
</a>
</div>
</div>
</div>
</div>

</section>

</section>
<!-- End Main Menu Area -->
<!-- Start Search Popup Area -->


<!-- End Footer Area -->
<!-- Back to top -->

<a class="scrolltop" href="#top"><i class="icofont-hand-drawn-up"></i></a>
<!-- End Back to top -->
<!-- jQuery Min JS -->

<!-- Prpper JS -->

<!-- Bootstrap Min JS -->

<!-- Classy Nav Min Js -->

<!-- Owl Carousel Min Js -->

<!-- Magnific Popup JS -->

<!-- CounterUp JS -->

<!-- Waypoints JS -->

<!-- Form Validator Min JS -->

<!-- Contact Form Min JS -->

<!-- Main JS -->

<!-- Global site tag (gtag.js) - Google Analytics -->






</body>
</html>
